MGTA-117 for Myelodysplasia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Myelodysplasia+1 MoreMGTA-117 - Biological
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to deplete cancer cells in people with AML or MDS-EB.

Eligible Conditions
  • Myelodysplasia
  • Acute Myeloid Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 0 Secondary · Reporting Duration: 21 days

21 days
Assess the clinically significant changes from baseline in vital signs, ECGs and laboratory parameters
Incidence rate of treatment emergent >= Grade 3 clinical laboratory abnormalities as assessed by CTCAE v5.0
Incidence rate of treatment emergent adverse events (TEAEs) leading to study drug discontinuation
Pharmacokinetics profile of MGTA-117
To establish a minimum safe and biologically effective dose

Trial Safety

Trial Design

1 Treatment Group

Single dose MGTA-117
1 of 1

Experimental Treatment

55 Total Participants · 1 Treatment Group

Primary Treatment: MGTA-117 · No Placebo Group · Phase 1

Single dose MGTA-117
Biological
Experimental Group · 1 Intervention: MGTA-117 · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 21 days

Who is running the clinical trial?

Magenta Therapeutics, Inc.Lead Sponsor
6 Previous Clinical Trials
162 Total Patients Enrolled

Eligibility Criteria

Age 18 - 75 · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have an estimated creatinine clearance of 60 mL/min or more.